Cefoxitin

Y. Vivian Tsai, Pharm.D., Edina Avdic, Pharm.D.

INDICATIONS

FDA

  • Note: many of the listed indications do not reflect contemporary use of this drug.
  • Lower respiratory tract infections
    • Including pneumonia and lung abscess
    • FDA-labeled but rarely used and not included in contemporary guideline-recommended pneumonia regimens.
  • Urinary tract infections
  • Intra-abdominal infections
    • Including peritonitis and intra-abdominal abscess (IDSA guidelines: mild-moderate community-acquired infections only)
      • While the older 2010 SIS/IDSA recommendation recommended cefoxitin for mild-to-moderate community-acquired infection, the 2017 SIS recommendation is specifically: do not use cefoxitin or cefotetan routinely for empiric therapy, Grade 2-B
  • Gynecologic infections
  • Septicemia caused by S. pneumoniae, S. aureus (MSSA), E. coli, Klebsiella species, and Bacteroides species including B. fragilis
    • FDA-labeled; generally not preferred for bloodstream infection because more reliably active and better-studied agents are available.
  • Bone and joint infections
    • FDA-labeled but rarely used; not preferred for MSSA osteoarticular infection.
  • Skin and skin-structure infections

NON-FDA APPROVED USES

  • Surgical prophylaxis (GI, abdominal hysterectomy, vaginal hysterectomy, Cesarean section)
  • Infections due to susceptible rapidly growing nontuberculous mycobacteria, principally M. abscessus complex, as one component of a multidrug regimen.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: September 6, 2026